NCT01134432View on ClinicalTrials.gov

Prednisolone +/- Addition of Anti-CD20 Antibody, Rituximab, in Patients With Immune Hemolytic Anemia

PHASE3CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions
Anemia, Hemolytic, Autoimmune
Interventions
DRUG

prednisolone + mabthera

"Prednisolone: 1,5 mg/kg for two weeks with gradually reduced dosis over two months.~Mabthera: 375 mg/m2 once a week for four weeks"

DRUG

Prednisolone

Prednisolone: 1,5 mg/kg for two weeks and then gradually reduced dosis over two months

Trial Locations (11)

DK-9000

Aalborg Hospital, Aalborg

DK-2100

Rigshospitalet - Copenhagen University Hospital, Copenhagen

DK-6700

Esbjerg Sygehus, Esbjerg

DK-6100

Haderslev Sygehus, Haderslev

DK-2730

Department of Haematology, Herlev Hospital, Herlev

DK-7500

Holstebro Sygehus, Holstebro

DK-4700

Naestved Sygehus, Næstved

DK-5000

Odense University Hospital, Odense

DK-4000

Roskilde Hospital, Roskilde

DK-7100

Vejle Hospital, Vejle

DK-8800

Viborg Sygehus, Viborg

All Listed Sponsors
lead

Copenhagen University Hospital at Herlev

OTHER

NCT01134432 - Prednisolone +/- Addition of Anti-CD20 Antibody, Rituximab, in Patients With Immune Hemolytic Anemia | Biotech Hunter | Biotech Hunter